Two tests and one reference [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2020-08-31 10:23 (231 d 00:49 ago) – Posting: # 21896
Views: 3,467

Hi Brus,

» If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?
» In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).
» If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?
» Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Here's a different way to look at it:
Can the same patient(s) be affected by your two tests? If yes, it is safer to use correction. If no, no correction should be necessary.

Pass or fail!

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 13 (0 registered, 13 guests [including 4 identified bots]).
Forum time: Monday 11:13 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz